

First patient enrolled in MGC ZAM App – CannEpi™ Clinical Trial

A
S
X

R
E
L
E
A
S
E

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') a European based pharmaceutical company specialising in the production and development of plant inspired medicines, has enrolled the first patient in the Company's proprietary data collection App and machine learning algorithm, ZAM, and will log the data from the commencement of an observational study monitoring the effects of MGC Pharma's epilepsy treatment, CannEpi™.

The app will record daily metrics from patients, their symptoms, and the impact of their treatment in order to establish a baseline. This will provide both medical practitioners and MGC Pharma with a detailed record of the study and an enhanced understanding of the effect of CannEpi™ on Refractory Epilepsy patients.

The App will not only provide the patients with reminders on how and when to take medication (per their medical practitioners' advice), but will also measure treatment progress, and have the ability for a qualified doctor to prescribe alternative medication following a consultation.

The trial is supported by the "I am Billy" Foundation, a charity set up to aid parents and families in navigating the challenges of obtaining NHS-funded Medical Cannabis for children.

Roby Zomer, co-founder and Managing Director of MGC Pharmaceuticals, commented: "The enrolment of the first patient in the ZAM App in the UK, enables us to fully record the impact and efficacy of our products undergoing trials. Consolidation of data is of paramount importance in ensuring the safety and efficiency of MGC's proprietary products, and we see the integration of both pharma and tech as a revolution in the clinical trial process.

"We are proud to be supporting the "I am Billy" foundation in this endeavour, and are pleased to be recognised as a leading company in the sector."

Authorised for release by the Board, for further information please contact:

MGC Pharmaceuticals Ltd

Roby Zomer
CEO & Managing Director
+61 8 6382 3390
info@mgcpharma.com.au

UK Financial and Corporate Advisor

SW4
Rupert Fane / Nilesh Patel
+44 7810 056 104
rf@hannam.partners / nilesh@hannam.partners

UK PR Advisors

Tavistock
Charles Vivian / Tim Pearson
+44 207 920 3150
mgcpharma@tavistock.co.uk

MGC Pharmaceuticals Ltd

Arron Canicais / Rowan Harland
Joint Company Secretaries
+61 8 6382 3390
info@mgcpharma.co.uk

UK Brokers

Peterhouse Capital
Charles Goodfellow / Lucy Williams
+44 207 469 0930
cg@peterhousecap.com / lw@peterhousecap.com

About I am Billy

I am Billy is a foundation set up to aid parents and families in navigating the challenges of obtaining NHS-funded Medical Cannabis for children. The foundation provides financial assistance in meeting the cost of cannabis based medical products (CBMPs) prescribed by a medical consultant, in addition to advancing the public understanding of the medical benefits of CBMPs.

About ZAM

ZAM, Medical Data App, will enable patients to log their medical history and monitor their medication use. Through the collection of patient data, the ZAM App will provide users with a more complete understanding of their health and treatment impact.

In addition to recording medical data, the ZAM App will provide patients with instructions on how and when to take medication (per their medical practitioner's advice), measure treatment progress, and have the ability for a qualified medical practitioner to prescribe alternative medication following an online consultation through telehealth services such as MGC Pharma's MCC based in Australia.

In time, an AI algorithm will use data collected from the ZAM App, including results from academic and clinical studies, to predict potential conflicting side effects from multiple treatments, as well as allowing users to order existing prescriptions, and provide the App user's medical practitioner with a comprehensive set of data on treatment and medical history.

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based pharmaceutical company, focused on developing and supplying accessible and ethically produced plant inspired medicines, combining in-house research with innovative technologies, with the goal of finding or producing treatments to for unmet medical conditions.

The Company's founders and executives are key figures in the global pharmaceuticals industry and the core business strategy is to develop and supply high quality plant inspired medicines for the growing demand in the medical markets in Europe, North America and Australasia.

MGC Pharma has a robust development pipeline targeting two widespread medical conditions and has further products under development.

MGC Pharma has partnered with renowned institutions and academia to optimise the development of targeted plant inspired medicines, to be produced in the Company's EU-GMP Certified manufacturing facilities.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

Follow us through our social media channels    